Michael Klichinsky
Fondateur chez CARISMA THERAPEUTICS, INC.
Fortune : 794 329 $ au 30/04/2024
Profil
Michael Klichinsky is the founder.
He founded CTx Operations, Inc. in 2016 and holds the title of Chief Scientific Officer.
He also founded Carisma Therapeutics, Inc. in 2016 and holds the title of Chief Scientific Officer.
Dr. Klichinsky has a doctorate degree from the University of Pennsylvania and a doctorate degree from the University of the Sciences in Philadelphia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/04/2024 | 484 347 ( 1,17% ) | 794 329 $ | 30/04/2024 |
Postes actifs de Michael Klichinsky
| Sociétés | Poste | Début |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Fondateur | 01/01/2016 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Fondateur | 01/01/2016 |
Formation de Michael Klichinsky
| University of Pennsylvania | Doctorate Degree |
| University of the Sciences in Philadelphia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
